Four anti-VEGF agents are available for AMD, including an aptamer of VEGF (pegaptanib), two anti-VEGF antibodies (bevacizumab and ranibizumab) and a VEGF trapping agent (aflibercept) [3–5]. This evidence concerns the gene VEGFA and age-related macular degeneration.